Introduction
The clinical manifestations and pharmacological management of acute organophosphate poisoning have been previously well described (Grob, 1956; Namba et al., 1971; Vale and Scott, 1974 With these clinical findings and the past history of chronic endogenous depression a provisional diagnosis of self-administered organophosphate poisoning was made. Blood was collected for serum cholinesterase assay, full blood count, serum electrolytes and liver function tests.
He was treated with atropine 0 6 mg i.v. with an immediate increase in pulse rate to 90 beats/min and BP to 135/65 mmHg. Pralidoxime 1 g. i.v. was given and resulted in reduction in secretions from the nose, oropharynx, trachea and skin, spontaneous small movements of hands and feet and some return, though diminished, of tendon reflexes. He remained unconscious, unresponsive and without spontaneous respiratory efforts. When stabilized he was transferred to the Intensive Care Unit (ICU) .
The finding of an empty bottle of coumaphos in the patient's locker at work the day following admission confirmed the provisional diagnosis. The ingested dose of coumaphos (0,0-diethyl-0-3-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl phosphorothioate) was estimated to be 14 g. The calculated LD50 for this man who weighed 85 kg was 1275 g (15 mg/kg).
Investigations After admission to the ICU, ward urine test showed heavy glycosuria and moderate ketonuria. Blood glucose level at that time was 15 mmol/l (normal limit, <8-9 mmol/l non-fasting state) but was 29-8 mmol/l when reviewed 90 min later. Serum cholinesterase concentration was 60 u./l (normal range 3000-6000 u.l).
Serum amylase concentration 3-5 hr after admission was 1397 u./l (normal range 70-300 u./l). This decreased to 301 u./l when re-examined 20 hr after admission.
Treatment and progress
Soluble insulin 20 u. subcutaneously was given after the blood glucose was found to be 29-8 mmol/l and using a 'sliding scale' of soluble insulin a further 16 u. of soluble insulin was given in divided doses over the next 12 hr. Twenty hr after admission the blood glucose was 10-6 mmol/l. No further insulin was needed and thereafter the blood glucose stayed within normal limits and the urine remained free of sugar.
An infusion of phenytoin sodium 125 mg/hr maintained to control convulsions was discontinued 16 hr after admission. Diazepam in 5 mg i.v. injections was used to control muscle fasciculations in the first 24 hr.
Pralidoxime was given by infusion of 6 g/24 hr for 12 days. Atropine 0-6 mg was given by i.m. injection every 6 hr and additional atropine 9.6 mg was given by i.v. injection when the pulse rate fell below 70 beats/min. Atropine was needed for 8 days.
Continuous cardiac monitoring was employed and he needed artificial ventilation for a total of 6 days. By the 2nd hospital day he exhibited occasional slight spontaneous movements and responded to painful stimuli. On as adequate respirations returned. He gradually gained muscle strength but when his orotracheal tube was removed on the 6th day he had persisting proximal muscle weakness. His physical signs continued to improve and on the 17th day after admission he was discharged from the ICU for in-patient psychiatric care. At this time he had recovered muscle strength but complained of a 'dizzy' feeling and was occasionally incontinent of urine. His serial serum cholinesterase concentrations are shown in Fig. 1 .
Discussion
The clinical effects of the anticholinesterase drugs are almost entirely due to the inhibition of acetylcholinesterase (AChE) whose physiological substrate is acetylcholine (ACh) (Namba et aL., 1971 Management of this patient followed accepted principles (Vale and Scott, 1974) and included the use of atropine to alleviate the muscarinic and central nervous system manifestations of organophosphate poisoning, pralidoxime to improve the force of muscular contraction and artificial ventilation to maintain adequate gas exchange.
Organophosphate poisoning should also cause predictable biochemical effects as the autonomic nervous system, which is modified by organophosphate, plays an important role in the regulation of insulin secretion. Stimulation of the vagus nerve (Kaneto, Kosaka and Nakao, 1967; Frohman, Ezdinli and Gavid, 1967) or the administration of parasympathomimetic agents (Malaisse et al., 1967; Kaneto et al., 1968) are both known to stimulate insulin secretion. Also vagotomy (Frohman et al., 1967) or cholinergic blockade (Permutt, Keller and Santiago, 1977) are known to inhibit insulin secretion (Permutt et al., 1977) . Therefore, the expected response to organophosphate would be stimulation of insulin secretion and a reduction in the blood glucose concentration. This is supported in the report of a case of temporary remission of diabetes mellitus in a patient following organophosphate poisoning (Samantray, 1978) . (Takahashi et al., 1980) . From theoretical analysis one would expect an increase in exocrine secretion of the pancreas and salivary glands in response to the increased muscarinic activity caused by the organophosphate. Whether this causes an abnormal increase in serum amylase is unknown. Thus the cause of the patient's metabolic and pancreatic response to the organophosphate poisoning remains unproved.
